Shareholder Daniel Walker Named 2020 D.C. Super Lawyer
Berger Montague is proud to announce that Thomson Reuters has named Shareholder Daniel Walker a 2020 D.C. Super Lawyer.
Each year, Super Lawyers selects attorneys using a patented multiphase selection process. Peer nominations and evaluations are combined with independent research, and each candidate is evaluated on 12 indicators of peer recognition and professional achievement. The objective is to create a credible, comprehensive, and diverse listing on outstanding attorneys that can be used as a resource for attorneys and consumers searching for legal counsel. No more than 5% of attorneys in any given state are selected by Super Lawyers to receive this honor.
Daniel Walker is a Shareholder of the Firm, which he rejoined in July 2017 after serving three years in the Health Care Division at the Federal Trade Commission. He leads the Firm’s Washington, D.C. office.
While at the Federal Trade Commission, Mr. Walker investigated and litigated antitrust matters in the health care industry. In addition to leading various nonpublic investigations in the pharmaceutical and health information technology sectors, Mr. Walker litigated Federal Trade Commission v. AbbVie Inc., et al., a case alleging that a brand pharmaceutical manufacturer engaged in sham patent litigation to delay generic competition, and Federal Trade Commission v. Cephalon Inc., a “pay-for-delay” lawsuit over a brand pharmaceutical manufacturer’s payment to four generic competitors in return for the generics’ agreement to delay entry into the market. The Cephalon case settled shortly before trial for $1.2 billion—the largest equitable monetary relief ever secured by the Federal Trade Commission—as well as significant injunctive relief.
During his time in private practice, Mr. Walker has litigated cases on behalf of plaintiffs and defendants in many areas of law, including antitrust, financial fraud, breach of contract, bankruptcy, and intellectual property. Mr. Walker has helped recover hundreds of millions of dollars on behalf of plaintiffs, including in In re Loestrin 24 Fe Antitrust Litigation (with $120 million settlement pending final approval), In re Titanium Dioxide Antitrust Litigation (with settlements totaling $163.5 million for purchasers of titanium dioxide), In re High Tech Employee Antitrust Litigation (with settlements totaling $435 million for workers in the high tech industry), and Adriana Castro, M.D., P.A., et al. v. Sanofi Pasteur Inc. (with $61.5 million settlement for purchasers of pediatric vaccines). Mr. Walker was also a member of the team that recovered the funds lost by account holders during MF Global’s collapse and a member of the trial team that successfully represented the Washington Mutual stockholders seeking to recover investments lost in the bankruptcy.
In addition, Mr. Walker has spoken frequently on antitrust issues, including on the intersection of antitrust and intellectual property in the health care industry.
Mr. Walker is a magna cum laude graduate of Amherst College and Cornell University Law School, where he was an Articles Editor for the Cornell Law Review. Before entering private practice, Mr. Walker clerked for the Honorable Richard C. Wesley of the United States Court of Appeals for the Second Circuit.